Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®
Launched by UNIVERSITY OF ZURICH · Dec 24, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Allogeneic stem cell transplantation
- • Male and female patients age 18-80
- • Signed informed consent after information
- Exclusion criteria:
- • Contra-indications due to ethical reasons
- • Unable to read or write
- • Unable to speak or understand the german language
- • Low-salt diet
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, Zh, Switzerland
Patients applied
Trial Officials
Rebecca Spirig, Prof MD
Principal Investigator
University Hospital Zurich, Centre of Clinical Nursing Science
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials